FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617991963> ?p ?o ?g. }

• W2617991963 endingPage "2567" @default.
• W2617991963 startingPage "2560" @default.
• W2617991963 abstract "DNA methyltransferase inhibitors sensitize leukemia cells to chemotherapeutics. We therefore conducted a phase 1/2 study of mitoxantrone, etoposide and cytarabine following 'priming' with 5-10 days of decitabine (dec/MEC) in 52 adults (median age 55 (range: 19-72) years) with relapsed/refractory acute myeloid leukemia (AML) or other high-grade myeloid neoplasms. During dose escalation in cohorts of 6-12 patients, all dose levels were well tolerated. As response rates appeared similar with 7 and 10 days of decitabine, a 7-day course was defined as the recommended phase 2 dose (RP2D). Among 46 patients treated at/above the RP2D, 10 (22%) achieved a complete remission (CR), 8 without measurable residual disease; five additional patients achieved CR with incomplete platelet recovery, for an overall response rate of 33%. Seven patients (15%) died within 28 days of treatment initiation. Infection/neutropenic fever, nausea and mucositis were the most common adverse events. While the CR rate compared favorably to a matched historic control population (observed/expected CR ratio=1.77), CR rate and survival were similar to two contemporary salvage regimens used at our institution (G-CLAC (granulocyte colony-stimulating factor (G-CSF); clofarabine; cytarabine) and G-CLAM (G-CSF; cladribine; cytarabine; mitoxantrone)). Thus, while meeting the prespecified efficacy goal, we found no evidence that dec/MEC is substantially better than other cytarabine-based regimens currently used for relapsed/refractory AML." @default.
• W2617991963 created "2017-06-05" @default.
• W2617991963 creator A5002286772 @default.
• W2617991963 creator A5008481093 @default.
• W2617991963 creator A5013626352 @default.
• W2617991963 creator A5028772063 @default.
• W2617991963 creator A5051018931 @default.
• W2617991963 creator A5057920623 @default.
• W2617991963 creator A5058189462 @default.
• W2617991963 creator A5058845981 @default.
• W2617991963 creator A5066251957 @default.
• W2617991963 creator A5074629157 @default.
• W2617991963 creator A5084791637 @default.
• W2617991963 creator A5086909430 @default.
• W2617991963 creator A5087100088 @default.
• W2617991963 creator A5088294011 @default.
• W2617991963 date "2017-05-30" @default.
• W2617991963 modified "2023-10-15" @default.
• W2617991963 title "Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study" @default.
• W2617991963 cites W1569756545 @default.
• W2617991963 cites W1606162789 @default.
• W2617991963 cites W1804439365 @default.
• W2617991963 cites W1904660196 @default.
• W2617991963 cites W1913413628 @default.
• W2617991963 cites W1980460837 @default.
• W2617991963 cites W1984814872 @default.
• W2617991963 cites W1995697319 @default.
• W2617991963 cites W2022240113 @default.
• W2617991963 cites W2024863226 @default.
• W2617991963 cites W2042450141 @default.
• W2617991963 cites W2044088883 @default.
• W2617991963 cites W2056080464 @default.
• W2617991963 cites W2063544405 @default.
• W2617991963 cites W2083462343 @default.
• W2617991963 cites W2086693204 @default.
• W2617991963 cites W2094703195 @default.
• W2617991963 cites W2098290171 @default.
• W2617991963 cites W2106658124 @default.
• W2617991963 cites W2106833395 @default.
• W2617991963 cites W2107810465 @default.
• W2617991963 cites W2109611268 @default.
• W2617991963 cites W2116363536 @default.
• W2617991963 cites W2141773875 @default.
• W2617991963 cites W2143820788 @default.
• W2617991963 cites W2143835472 @default.
• W2617991963 cites W2144395887 @default.
• W2617991963 cites W2159507916 @default.
• W2617991963 cites W2214515641 @default.
• W2617991963 cites W2313888337 @default.
• W2617991963 cites W2466569700 @default.
• W2617991963 cites W4231346141 @default.
• W2617991963 doi "https://doi.org/10.1038/leu.2017.165" @default.
• W2617991963 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5709258" @default.
• W2617991963 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28555084" @default.
• W2617991963 hasPublicationYear "2017" @default.
• W2617991963 type Work @default.
• W2617991963 sameAs 2617991963 @default.
• W2617991963 citedByCount "24" @default.
• W2617991963 countsByYear W26179919632018 @default.
• W2617991963 countsByYear W26179919632019 @default.
• W2617991963 countsByYear W26179919632020 @default.
• W2617991963 countsByYear W26179919632021 @default.
• W2617991963 countsByYear W26179919632022 @default.
• W2617991963 countsByYear W26179919632023 @default.
• W2617991963 crossrefType "journal-article" @default.
• W2617991963 hasAuthorship W2617991963A5002286772 @default.
• W2617991963 hasAuthorship W2617991963A5008481093 @default.
• W2617991963 hasAuthorship W2617991963A5013626352 @default.
• W2617991963 hasAuthorship W2617991963A5028772063 @default.
• W2617991963 hasAuthorship W2617991963A5051018931 @default.
• W2617991963 hasAuthorship W2617991963A5057920623 @default.
• W2617991963 hasAuthorship W2617991963A5058189462 @default.
• W2617991963 hasAuthorship W2617991963A5058845981 @default.
• W2617991963 hasAuthorship W2617991963A5066251957 @default.
• W2617991963 hasAuthorship W2617991963A5074629157 @default.
• W2617991963 hasAuthorship W2617991963A5084791637 @default.
• W2617991963 hasAuthorship W2617991963A5086909430 @default.
• W2617991963 hasAuthorship W2617991963A5087100088 @default.
• W2617991963 hasAuthorship W2617991963A5088294011 @default.
• W2617991963 hasBestOaLocation W26179919632 @default.
• W2617991963 hasConcept C104317684 @default.
• W2617991963 hasConcept C126322002 @default.
• W2617991963 hasConcept C143998085 @default.
• W2617991963 hasConcept C150194340 @default.
• W2617991963 hasConcept C190727270 @default.
• W2617991963 hasConcept C2776694085 @default.
• W2617991963 hasConcept C2777063308 @default.
• W2617991963 hasConcept C2778041864 @default.
• W2617991963 hasConcept C2778119113 @default.
• W2617991963 hasConcept C2778461978 @default.
• W2617991963 hasConcept C2778496288 @default.
• W2617991963 hasConcept C2778729363 @default.
• W2617991963 hasConcept C2779200787 @default.
• W2617991963 hasConcept C2780235182 @default.
• W2617991963 hasConcept C2780775027 @default.
• W2617991963 hasConcept C2780923524 @default.
• W2617991963 hasConcept C2908647359 @default.
• W2617991963 hasConcept C55493867 @default.

• next